THE NEXT KILLER VACCINE OF RSV IS GOING INTO PEOPLES ARMS.ESPECIALLY PREGNANT WOMEN.AS WE SPEAK.

 
THE NEXT KILLER VACCINE OF RSV IS GOING INTO PEOPLES ARMS.ESPECIALLY PREGNANT WOMEN.AS WE SPEAK.

DISEASES-ANIMAL TO HUMAN ( 500 million Dead )

REVELATION 6:7-8
7 And when he had opened the fourth seal, I heard the voice of the fourth beast say, Come and see.
8 And I looked, and behold a pale horse:(CHLORES GREEN) and his name that sat on him was Death, and Hell followed with him. And power was given unto them over the fourth part of the earth,(2 billion) of (8 billion) to kill with sword,(WEAPONS)(500 million) and with hunger,(FAMINE)(500 million) and with death,(INCURABLE DISEASES)(500 million) and with the beasts of the earth.(ANIMAL TO HUMAN DISEASE)(500 million).

DRUG PUSHERS AND ADDICTS

1 PET 5:8
8 Be sober,(NOT DRUGED UP OR ALCOHOLICED) be vigilant; because your adversary the devil, as a roaring lion, walketh about, seeking whom he may devour:

REVELATION 18:23
23 And the light of a candle shall shine no more at all in thee; and the voice of the bridegroom and of the bride shall be heard no more at all in thee: for thy merchants were the great men of the earth; for by thy sorceries (DRUGS) were all nations deceived.

REVELATION 9:21 (RAGE OF THE LAST DAYS AGE SATAN WORSHIP AND DRUG SELLING AND JUNKIES)(THEY REFUSE TO REPENT OF THESE SINS)
21 Neither repented they of their murders,(KILLING) nor of their sorceries (DRUG ADDICTS AND DRUG PUSHERS), nor of their fornication,(SEX OUTSIDE MARRIAGE OR PROSTITUTION FOR MONEY) nor of their thefts.(STEALING)

WELL HERE AT THE OLD AGE HOME I'M IN. I WAS JUST ASKED IF I WANTED TO CONSENT TO TAKING RSV VACCINE SHOTS YESTERDAY. I SAID NO THANKS. AND THE NURSE THEN CARRIED ONTO THE NEXT ROOM.I DO SAY THIS SAYING TO SOME OF THE NURSES. WELL IF I'M GOING TO DIE OF A HEART ATTACK. ITS GOING TO BE BECAUSE I'M TO FAT. NOT BECAUSE OF ANY VACCINE SHOT. YES THE NEW AND IMPROVED KILLER RSV VACCINE IS READY TO BE SHOT IN YOUR ARM. BE A GOOD LITTLE SLAVE AND TAKE YOUR SHOT SAYS DADDYS LITTLE BOY JUSTIN.AND TAM AT HEALTH CANADA..

Health Canada approves 1st RSV vaccine for people 60 and older-Shot expected to be available in 'limited' amounts this year-Jennifer La Grassa · CBC · Posted: Aug 04, 2023 5:29 PM EDT |-Health Canada approves RSV vaccine for people 60 and older.

Health Canada has approved the first vaccine for respiratory syncytial virus (RSV) for adults age 60 and over, but it may only be available in "limited" quantities for this fall's respiratory virus season.RSV is a common but highly contagious virus that appears like a common cold for most people. In more vulnerable populations, RSV can cause bronchiolitis — the inflammation of the small airways in the lung — or pneumonia, say experts. Health Canada approved manufacturer GSK's new vaccine called Arexvy on Friday. In an email to CBC News, the federal health body confirmed that it anticipates a limited supply of the vaccine will be available for the upcoming RSV season. This news comes after the U.S. Food and Drug Administration (FDA) gave their approval for the vaccine in May. "It will be a game changer in significantly preventing severe illness and death, especially amongst older Canadians," said Dr. Samir Sinha, the director of geriatrics at Sinai Health and University Health Network in Toronto. Doctors have been calling for an RSV vaccine for seniors because although the virus is common, people who are older are more likely to become severely ill and need hospitalization. First RSV vaccine approved in U.S. after decades of attempts-"This has been decades long in the making," Dr. Isaac Bogoch, an infectious disease specialist with the University Health Network in Toronto, said of the vaccine's approval. "It's a very tough virus, it can have negative health impacts. It [can] lead to hospitalization, intensive care unit stays, even death,"  Bogoch added. "And it's wonderful to have a vaccine that … appears to significantly reduce the risk of severe lower respiratory tract disease." Dr. Samir Sinha stands outside a hospital, wearing a white lab coat. He's looking directly into the camera.Dr. Samir Sinha, director of geriatrics at Sinai Health System and the University Health Network in Toronto, says he will be recommending the vaccine to all of his elderly patients once its made available. (Ousama Farag/CBC)-RSV not well-tracked in Canada: experts-It's unclear how many people 60 and older in Canada are hospitalized or die from the illness, as experts say it's not properly tracked.According to Sinha, Canada isn't properly screening for RSV and the illness itself can be hard to detect — making the exact burden unclear. But he estimates that it can be similar to the rates of hospitalizations and death seen with influenza — if not worse as the virus can spread more rapidly and symptoms may take a few days to develop.In Canada, 12,200 people are hospitalized and 3,500 die from influenza annually. Vaccine offers more than 80% protection, says GSK-In a news release issued Friday, GSK said a randomized clinical trial showed the vaccine has an 82 per cent efficacy in preventing lower respiratory tract disease caused by RSV, compared to seniors who got a placebo.The company said it also showed a 94 per cent efficacy in preventing the illness in seniors with underlying medical conditions."I think this vaccine will go a long way based on the results that are available … the vaccine appeared to be safe and appeared to provide very significant protection," said Bogoch. THE DOSE-It took 60 years, but RSV vaccines are just around the corner — and could make a big difference-He added that if the infection spreads to the lower respiratory tract, it can make it hard for people to breathe so that they need "supplemental oxygen." This is when people typically end up in hospital. Sinha said RSV infections can also "trigger other problems in the body," like a bacterial or viral pneumonia. "So it's not necessarily that if you get RSV you're going to die of that infection, but what you might do is trigger other heart or other lung complications that then can actually cost you your life potentially," he said. National guidance for the shot expected in 2024.RSV season in Canada usually starts in the late fall and lasts until spring. Health Canada said the vaccine is a single dose injection, but it's unclear whether people will need to get the vaccine every year or a booster. St. Joseph's Healthcare Hamilton infectious disease physician Dr. Zain Chagla said available data suggests that people who get the vaccine will be protected for up to two years. But beyond that, he said further research is needed. "Hopefully this [vaccine] gets in before RSV season, but if an older adult accesses the vaccine afterwards, they still could get a couple years benefit," he said. In an email to CBC News, Health Canada said that guidance from the National Advisory Committee on Immunization (NACI) on the use of the vaccine is expected next year. Drug to help prevent serious RSV illness in babies approved by Health Canada-It said that based on consultations with Canadian experts, NACI has "first prioritized (and is currently developing) advice for RSV products to protect infants before developing advice for older adults."It added that it will be up to individual provinces and territories to decide if they will work Arexvy into their existing RSV programs — and if so, it will work with them individually. Experts like Sinha say they also hope the Canadian government considers covering the cost of the vaccine as that can often be a "barrier to access," especially in more vulnerable populations. Sinha said that as soon as the vaccine is made available, he'll be recommending that all his patients get the shot. What about kids? Last winter was an especially bad season of RSV in the country, specifically for young kids. In addition to seniors, infants are at a higher risk of getting very sick with RSV. There is no RSV vaccine for children, but there are two kinds of antibody injections that can be given to high-risk babies to help prevent serious illness.  One of them, palivizumab, has often been given to babies who were born prematurely – but it needs to be injected about once a month during RSV season to stay effective. A new antibody drug – nirsevimab, also known by the brand name Beyfortus – was approved by Health Canada in April. Nirsevimab only requires one injection to protect babies during the RSV season. It's not yet known how widely it will be recommended for babies in Canada this fall.  On Thursday, the Centers for Disease Control and Prevention (CDC) in the U.S. recommended that babies born just before or during the RSV season, as well as babies who are less than eight months old before the season starts, should get the nirsevimab shot. The CDC also recommended that the shot should be given to some eight to 19-month-old babies who are at higher risk of getting seriously ill from the virus. 

Contact Us-Health Canada Approves Pfizer’s Bivalent Respiratory Syncytial Virus (RSV) Vaccine for Older Adults and Infants Through Maternal Immunization-04/01/2024

Health Canada’s approval of ABRYSVO helps to address the urgent need to minimize the spread of RSV infections – a disease with flu-like symptoms that can result in respiratory distress1,2,3, and lead to serious infection such as bronchitis or pneumonia, requiring hospital treatment4
ABRYSVO is the only RSV vaccine authorized in Canada for maternal immunization-Kirkland, QC, January 4, 2023 - Pfizer Canada ULC announces the Health Canada approval of ABRYSVOTM, its bivalent Respiratory Syncytial Virus (RSV) vaccine. The vaccine is indicated for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older by active immunization, and the prevention of lower respiratory tract disease and severe lower respiratory tract disease caused by RSV in infants from birth through 6 months of age by active immunization of pregnant individuals.RSV is a common respiratory virus that causes mild disease with cold-like symptoms. In more vulnerable populations, like adults 60 and over, an RSV infection can be severe, especially among those with underlying respiratory or cardiac conditions5. For infants, RSV infection can result in respiratory distress, especially in those less than six months of age, and those with higher risk factors such as congenital heart or lung disease, or prematurity6,7,8.“RSV is a virus that spreads easily and is very difficult to completely avoid,” said Laura Tamblyn Watts, founder and CEO of CanAge. “Older adults living in congregate settings or long-term care, which is over 500,000 Canadians9, have a higher risk of becoming infected with RSV10.  It’s important for all of us to be mindful of RSV prevention to help protect our loved ones and more vulnerable populations.““Today’s announcement means Canada has a new option to help protect those most at risk from the severity of RSV infections,” said Andréa Mueller, Primary Care Portfolio Lead at Pfizer Canada. “For those eligible to receive the vaccine, getting vaccinated means helping to ensure babies are protected from their first breath, and helping older adults continue doing what they love with minimized risk of becoming infected. At Pfizer, we take pride in our decades of experience in vaccines, helping to make a positive contribution to public health and the broader community.” Respiratory viruses, including RSV, increase in the fall and winter months, and the impact of RSV on healthcare resources is significant. RSV infection can result in hospitalization, particularly for infants one year or younger, for whom there is an increased risk11. Older adults also have some of the highest costs associated with the disease12. The approval of Pfizer’s vaccine will help to protect those at both early and later stages in life and will reduce the overall health and economic impact of RSV infection12.“Vaccines are considered to be the most effective tool in public health for preventing illness and can help reduce the stress on our healthcare system and professionals including nurses, doctors, and others on the frontline,” said Dr. Darine El-Chaâr, Maternal Fetal Medicine physician at The Ottawa Hospital. “Vaccines administered through maternal immunization can also help play a critical role in decreasing the gap of vulnerability in the first few months of an infant’s life, as well as helping to protect their mothers, who may be at increased risk of severe disease compared with non-pregnant women13. ” Pfizer Canada is currently assessing the timeline of availability for ABRYSVO and is committed to bringing supply of this vaccine to Canadians as quickly as possible.

About Pfizer Canada (WORLD BIGGEST DRUG (PHARMACIA (DRUG STORE) DEALER.
Pfizer Canada ULC is the Canadian operation of Pfizer Inc., one of the world's leading biopharmaceutical companies. Our diversified health care portfolio includes some of the world's best known and most prescribed medicines and vaccines. We apply science and our global resources to improve the health and well-being of Canadians at every stage of life. Our commitment is reflected in everything we do, from our disease awareness initiatives to our community partnerships. To learn more about Pfizer Canada, visit pfizer.ca or you can follow us on LinkedIn, Facebook, Twitter or YouTube.For further information:Corporate Affairs Canada-1-866-9PFIZER (1-866-973-4937) corporate.affairs.canada@pfizer.com

References
[1] Centers for Disease Control & Prevention. Respiratory Syncytial Virus Infection (RSV). https://www.cdc.gov/rsv/index.html
[2] Vaccine. 2020 Mar 4; 38(11): 2435–2448. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049900/
[3] Government of Canada. Respiratory syncytial virus (RSV): For health professionals. https://www.canada.ca/en/public-health/services/diseases/respiratory-syncytial-virus-rsv/health-professionals.html
[4] The Lung Association. Respiratory Syncytial Virus (RSV). https://www.lung.ca/lung-health/lung-disease/respiratory-syncytial-virus-rsv
[5] Government of Canada. Respiratory syncytial virus: Canadian Immunization Guide. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/respiratory-syncytial-virus.html
[6] Centers for Disease Control & Prevention. Respiratory Syncytial Virus Infection (RSV). https://www.cdc.gov/rsv/index.html
[7] Vaccine. 2020 Mar 4; 38(11): 2435–2448. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049900/
[8] Government of Canada. Respiratory syncytial virus (RSV): For health professionals. https://www.canada.ca/en/public-health/services/diseases/respiratory-syncytial-virus-rsv/health-professionals.html
[9] Statistics Canada. Impacts of the COVID-19 pandemic in nursing and residential care facilities in Canada. https://www150.statcan.gc.ca/n1/pub/45-28-0001/2021001/article/00025-eng.htm
[10] Health Link BC. Respiratory Syncytial Virus (RSV) Infection. https://www.healthlinkbc.ca/illnesses-conditions/infectious-diseases/respiratory-syncytial-virus-rsv-infection
[11] Wingert A, Pillay J, Moore DL, Guitard S, Vandermeer B, Dyson MP, Sinilaité A, Tunis M, Hartling L. Burden of illness in infants and young children hospitalized for respiratory syncytial virus: A rapid review. Can Commun Dis Rep 2021;47(9):381–96. https://doi.org/10.14745/ccdr.v47i09a05
[12] Rafferty, E., Paulden, M., Buchan, S.A. et al. Evaluating the Individual Healthcare Costs and Burden of Disease Associated with RSV Across Age Groups. PharmacoEconomics. https://link.springer.com/article/10.1007/s40273-022-01142-w#citeas
[13] Esposito et al. RSV Prevention in All Infants: Which Is the Most Preferable Strategy? Front. Immunol. https://www.frontiersin.org/articles/10.3389/fimmu.2022.880368/full